Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Ожирение (инсулинорезистентность) и бесплодие – две стороны одной медали: патогенетические взаимодействия и возможности современной фармакотерапии
Ожирение (инсулинорезистентность) и бесплодие – две стороны одной медали: патогенетические взаимодействия и возможности современной фармакотерапии
Калинченко С.Ю., Тюзиков И.А., Ворслов Л.О. и др. Ожирение (инсулинорезистентность) и бесплодие – две стороны одной медали: патогенетические взаимодействия и возможности современной фармакотерапии. Consilium Medicum. 2015; 17 (4): 51–58.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В обзорной статье на основе новейших научных данных и результатов собственных клинических исследований рассматриваются вопросы патогенетических связей ожирения, инсулинорезистентности и нарушений репродуктивной функции мужчин. Все анализируемые проблемы являются сегодня крайне актуальными андрологическими трендами ввиду неуклонного роста как частоты ожирения и инсулинорезистентности, так и бесплодия в мужской популяции, что, безусловно, свидетельствует о наличии тесных патогенетических связей между ними. Ожирение и инсулинорезистентность – системные факторы окислительного стресса сперматозоидов независимо от других (в том числе урологических) возможных причин мужской инфертильности, и клинический опыт показывает, что без их своевременной диагностики и активной патогенетической фармакотерапии улучшения репродуктивной функции бесплодного мужчины ожидать не следует. С другой стороны, в арсенале эндокринологов уже сегодня есть эффективные и репродуктивно безопасные препараты для коррекции ожирения и инсулинорезистентности, что позволяет рекомендовать их для более широкого применения в рутинной андрологической практике. Решение проблемы фармакотерапии мужского бесплодия у метаболически дискредитированных пациентов возможно только на основе междисциплинарного подхода, для чего необходимо более детально информировать практикующих андрологов как о механизмах влияния ожирения и инсулинорезистентности на сперматогенез, так и о современных патогенетических подходах к их ликвидации у всех мужчин с бесплодием.
Ключевые слова: ожирение, инсулинорезистентность, мужское бесплодие, окислительный стресс, патогенетические связи, диагностика, фармакотерапия.
Key words: obesity, insulin resistance, male infertility, oxidative stress, pathogenetic links, diagnosis, drug therapy.
Ключевые слова: ожирение, инсулинорезистентность, мужское бесплодие, окислительный стресс, патогенетические связи, диагностика, фармакотерапия.
________________________________________________
Key words: obesity, insulin resistance, male infertility, oxidative stress, pathogenetic links, diagnosis, drug therapy.
Полный текст
Список литературы
1. Современная демографическая ситуация в РФ. Отчет Роскомстата, 2010. www.hppt: gks.ru>wps/wcm/connect/rosstat…main…demography/. / Sovremennaia demograficheskaia situatsiia v RF. Otchet Roskomstata, 2010. www.hppt: gks.ru>wps/wcm/connect/rosstat…main…demography/. [in Russian]
2. Предположительная численность населения Российской Федерации до 2025 года. Ежегодный справочник. М.: Федеральная служба государственной статистики РФ, 2005. / Predpolozhitel'naia chislennost' naseleniia Rossiiskoi Federatsii do 2025 goda. Ezhegodnyi spravochnik. M.: Federal'naia sluzhba gosudarstvennoi statistiki RF, 2005. [in Russian]
3. Chavarro JE, Toth TL, Wright DL et al. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril 2010; 93: 2222–31.
4. Hammoud AO, Wilde N, Gibson M et al. Male obesity and alteration in sperm parameters. Fertil Steril 2008; 90: 2222–5.
5. Crujeiras AB, Casanueva FF. Obesity and the reproductive system disorders: epigenetics as a potential bridge. Hum Reprod Update 2014. pii: dmu060. [Epub ahead of print]
6. Klenov VE, Jungheim ES. Obesity and reproductive function: a review of the evidence. Curr Opin Obstet Gynecol 2014; 26 (6): 455–60.
7. Gustafson B, Hammarstedt А, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2276–83.
8. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347–55.
9. Sánchez-Lara K, Morales-Graf L, Green D. Сancer and obesity. Cancer Causes Control 2011; 22 (2): 291–9.
10. Ройтберг Г.Е. Метаболический синдром. М.: МЕДпресс-информ, 2007. / Roitberg G.E. Metabolicheskii sindrom. M.: MEDpress-inform, 2007. [in Russian]
11. Калинченко С.Ю., Тишова Ю.А., Тюзиков И.А., Ворслов Л.О. Ожирение и метаболический синдром у мужчин. М.: Практическая медицина, 2014. / Kalinchenko S.Iu., Tishova Iu.A., Tiuzikov I.A., Vorslov L.O. Ozhirenie i metabolicheskii sindrom u muzhchin. M.: Prakticheskaia meditsina, 2014. [in Russian]
12. Панков Ю.А. Жировая ткань как эндокринный орган, регулирующий рост, половое созревание и другие физиологические функции. Биохимия. 1999; 64: 601–9. / Pankov Iu.A. Zhirovaia tkan' kak endokrinnyi organ, reguliruiushchii rost, polovoe sozrevanie i drugie fiziologicheskie funktsii. Biokhimiia. 1999; 64: 601–9. [in Russian]
13. Lyon CJ et al. Mini-review: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195–200.
14. Könner AC, Brüning JC. Selective insulin and leptin resistance in metabolic disorders. Cell Metab 2012; 16 (2): 144–52.
15. Coppari R, Bjørbæk C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov 2012; 11 (9): 692–708.
16. Jung CH, Kim MS. Molecular mechanisms of central leptin resistance in obesity. Arch Pharm Res 2013; 36 (2): 201–7.
17. Paz-Filho G, Mastronardi C, Franco CB et al. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arq Bras Endocrinol Metab 2012; 56 (9): 597–607.
18. Roncavi DAK, van RLR. Promotion of human adipocite precursor replication by 17b-estradiol in culture. J Clin Invest 1977; 62: 503–8.
19. Dobs AS, Bachorik PS, Arver S et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab 2001; 86 (3): 1026–33.
20. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89 (6): 2548–56.
21. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.
22. American Diabetes association. Standards of medical care in diabetes. Diabetes Care 2008; 31: 12–54.
23. Shoelson SE, Herrero L, Naaz A. Obesity, Inflammation, and Insulin Resistance. Gastroenterology 2007; 132 (6): 2169–80.
24. Schmidt MI, Saad MJA, Duncan BB. Subclinical inflammation and obesity, diabetes and related disorders. Drug Discovery Today: Disease Mechanisms 2005; 2 (3): 307–12.
25. Kadowaki T, Yamauchi T, Kubota N et al. Role of adipokines in obesity-linked insulin resistance, metabolic syndrome and atherosclerosis. Atherosclerosis Suppl 2006; 7 (3): 164–70.
26. Astrup A, Finer N. Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'? Obes Rev 2000; 1 (2): 57–9.
27. Kalra S. Diabesity. J Pak Med Assoc 2013; 63 (4): 532–4; Bailey CJ. New therapies for diabesity. Curr Diab Rep 2009; 9 (5): 360–7.
28. Colagiuri S. Diabesity: therapeutic options. Diabetes Obes Metab 2010; 12 (6): 463–73.
29. Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med 2003; 41 (9): 1120–30.
30. Божедомов В.А., Громенко Д.С., Ушакова И.В. Причины оксидативного стресса сперматозоидов. Проблемы репродукции. 2008; 6: 67–73. / Bozhedomov V.A., Gromenko D.S., Ushakova I.V. Prichiny oksidativnogo stressa spermatozoidov. Problemy reproduktsii. 2008; 6: 67–73. [in Russian]
31. Божедомов В.А., Громенко Д.С., Ушакова И.В. Оксидативный стресс сперматозоидов в патогенезе мужского бесплодия. Урология. 2009; 2: 51–6. / Bozhedomov V.A., Gromenko D.S., Ushakova I.V. Oksidativnyi stress spermatozoidov v patogeneze muzhskogo besplodiia. Urologiia. 2009; 2: 51–6. [in Russian]
32. Villegas J, Schulz M, Soto L et al. Influence of reactive oxygen species produced by activated leukocytes at the level of apoptosis in mature human spermatozoa. Fertil Steril 2005; 83: 808–10.
33. Zorn B, Vidmar G, Meden-Vrtovec H. Seminal reactive oxygen species as predictors of fertilization, embryo quality and pregnancy rates after conventional in vitro fertilization and intracytoplasmic sperm injection. Int J Androl 2003; 26: 279–85.
34. Koppers AJ, Mitchell LA, Wang P et al. Phosphoinositide 3-kinase signalling pathway involvement in a truncated apoptotic cascade associated with motility loss and oxidative DNA damage in human spermatozoa. Biochem J 2011; 436 (3): 687–98.
35. Kemal Duru N, Morshedi M, Oehninger S. Effects of hydrogen peroxide on DNA and plasma membrane integrity of human spermatozoa. Fertil Steril 2000; 74: 1200–7.
36. Tremellen K. Oxidative stress and male infertility – a clinical perspective. Hum Reprod Update 2008; 14 (3): 243–58.
37. Showell MG, Brown J, Yazdani A et al. Antioxidants for male subfertility. Cochrane Database Syst Rev 2011; 1: CD007411.
38. Sarkar O, Bahrainwala J, Chandrasekaran S et al. Impact of inflammation on male fertility. Front Biosci (Elite Ed) 2011; 3: 89–95.
39. Eisenberg ML, Lipshultz LI. Varicocele-induced infertility: Newer insights into its pathophysiology. Indian J Urol 2011; 27 (1): 58–64.
40. Perez-Crespo M, Pintado B, Gutierrez-Adan A. Scrotal heat stress effects on sperm viability, sperm DNA integrity, and the offspring sex ratio in mice. Mol Reprod Dev 2007; 75: 40–7.
41. Kasturi SS, Tannir J, Brannigan RE. The metabolic syndrome and male infertility. J Androl 2008; 29: 251–9.
42. Brannian JD. Obesity and fertility S D Med 2011; 64 (7): 251–4.
43. Pasquali R, Patton L, Gambineri A. Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007; 14 (6): 482–7.
44. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic Syndrome and Urological Diseases Rev Urol 2010; 12 (4): 157–80.
45. Pasquali R, Patton L, Gambineri A. Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007; 14 (6): 482–7.
46. Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol 2010; 316 (2): 180–6.
47. Тюзиков И.А. Метаболический синдром и мужское бесплодие. Андрология и генитальная хирургия. 2013; 2: 5–10. / Tiuzikov I.A. Metabolicheskii sindrom i muzhskoe besplodie. Andrologiia i genital'naia khirurgiia. 2013; 2: 5–10. [in Russian]
48. Stewart TM, Liu DY, Garrett C et al. Associations between andrological measures, hormones and semen quality in fertile Australian men: inverse relationship between obesity and sperm output. Hum Reprod 2009; 24: 1561–8.
49. Chavarro JE, Toth TL, Wright DL et al. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril 2010; 93: 2222–31.
50. Hammoud AO, Wilde N, Gibson M et al. Male obesity and alteration in sperm parameters. Fertil Steril 2008; 90: 2222–5.
51. Lee MJ, Fried SK. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab 2009; 296: 1230–8.
52. Luukkaa V, Pesonen U, Huhtaniemi I et al. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998; 83 (9): 3243–6.
53. Kapoor D, Clarke S, Stanworth R. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007; 156: 595–602.
54. Kalinchenko SY, Tishova YA, Rozhivanov RV, Mskhalaya GJ. Leptin and its negative influence on testosterone secretion in obese men with late onset hypogonadism. Presented at XVIII World Congress of the WAS, 1st World Congress for Sexual Health. April 15–19, 2007. Sydney, Australia. Abstract book 2007, OP1-12.
55. Goulis DG, Tarlatzis BC. Metabolic syndrome and reproduction: I. testicular function. Gynecol Endocrinol 2008; 24 (1): 33–9.
56. Павлова З.Ш., Тишова Ю.А., Калинченко С.Ю. и др. Актуальные проблемы XXI века: мужское бесплодие, ожирение, дефицит витамина D – есть ли взаимосвязь? Московский уролог. 2014; 6: 19–21. / Pavlova Z.Sh., Tishova Iu.A., Kalinchenko S.Iu. i dr. Aktual'nye problemy XXI veka: muzhskoe besplodie, ozhirenie, defitsit vitamina D – est' li vzaimosviaz'? Moskovskii urolog. 2014; 6: 19–21. [in Russian]
57. Тюзиков И.А. Гормон D-статус у мужчин с андрологической патологией (пилотное исследование). Материалы Международного конгресса «Мужское здоровье». Минск, 2014; с. 90–2. / Tiuzikov I.A. Gormon D-status u muzhchin s andrologicheskoi patologiei (pilotnoe issledovanie). Materialy Mezhdunarodnogo kongressa «Muzhskoe zdorov'e». Minsk, 2014; s. 90–2. [in Russian]
58. Тюзиков И.А., Калинченко С.Ю., Ворслов Л.О. Тишова Ю.А. Витамин D, мужское здоровье и мужская репродукция. Андрология и генитальная хирургия. 2013; 4: 36–44. / Tiuzikov I.A., Kalinchenko S.Iu., Vorslov L.O. Tishova Iu.A. Vitamin D, muzhskoe zdorov'e i muzhskaia reproduktsiia. Andrologiia i genital'naia khirurgiia. 2013; 4: 36–44. [in Russian]
59. Тюзиков И.А., Калинченко С.Ю., Ворслов Л.О. Тишова Ю.А. Витамин D, мужское здоровье и предстательная железа (обзор литературы). Андрология и генитальная хирургия. 2014; 3: 26–32. / Tiuzikov I.A., Kalinchenko S.Iu., Vorslov L.O. Tishova Iu.A. Vitamin D, muzhskoe zdorov'e i predstatel'naia zheleza (obzor literatury). Andrologiia i genital'naia khirurgiia. 2014; 3: 26–32. [in Russian]
60. Kalyani RR, Dobs AS. Androgen deficiency, diabetes and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007; 14: 226–34.
61. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003; 14: 281–7.
62. Weinberg JM. Lipotoxicity. Kidney Int 2006; 70 (9): 1560–6.
63. Aitken RJ, Krausz C. Oxidative stress, DNA damage and the Y chromosome. Reproduction 2001; 122: 497–506.
64. Garrido N, Meseguer M, Alvarez J et al. Relationship among standard semen parameters, glutathione peroxidase/glutathione reductase activity, and mRNA expression and reduced glutathione content in ejaculated spermatozoa from fertile and infertile men. Fertil Steril 2004; 82 (Suppl. 3): 1059–66.
65. Sarkar O, Bahrainwala J, Chandrasekaran S et al. Impact of inflammation on male fertility. Front Biosci (Elite Ed) 2011; 3: 89–95.
66. Nguyen RH, Wilcox AJ, Skaerven R et al. Men’s body mass index and infertility. Hum Reprod 2007; 22: 2488–93.
67. Ohwaki K, Endo F, Yano E. Relationship between body mass index and infertility in healthy male Japanese workers: a pilot study. Andrologia 2009; 41: 100–4.
68. Bener A, Al-Ansari AA, Zirie M et al. Is male fertility associated with type 2 diabetes mellitus? Int Urol Nephrol 2009; 41: 777–84.
69. Kort HI, Massey JB, Elsner CW et al. Impact of body mass index values on sperm quantity and quality. J Androl 2006; 27: 450–52.
70. Fejes I, Koloszár S, Szöllosi J et al. Is semen quality affected by male body fat distribution? Andrologia 2005; 37: 155–9.
71. Ali ST, Shaikh RN, Siddiqi AN et al. Semen analysis in insulin-dependent/noninsulin-dependent diabetic men with/without neuropathy. Arch Androl 1993; 30: 47–54.
72. Dohle GR, Diemer T, Giwercman A et al. Male Infertility Guideline. EAU, 2012.
73. Vinik AI, Maser RE, Mitchell BD et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553–79.
74. Gilja I, Parazajder J, Radej M et al. Retrograde ejaculation and loss of emission: possibilities of conservative treatment. Eur Urol 1994; 25: 226–8.
75. El-Sakka AI. Premature ejaculation in noninsulin- dependent diabetic patients. Int J Androl 2003; 26: 329–34.
76. Shiraishi K, Takihara H, Matsuyama H. Elevated scrotal temperature, but not varicocele grade, reflects testicular oxidative stress-mediated apoptosis. World J Urol 2010; 28: 359–64.
77. Tsao CW, Hsu CY, Chou YC et al. The relationship between varicoceles and obesity in a young adult population. Int J Androl 2009; 32: 385–90.
78. Handel LN, Shetty R, Sigman M. The relationship between varicoceles and obesity. J Urol 2006; 176: 2138–40.
79. Shafik A, Olfat S. Scrotal lipomatosis. Br J Urol 1981; 53: 50–4.
80. Shafik A, Olfat S. Lipectomy in the treatment of scrotal lipomatosis. Br J Urol 1981; 53: 55–61.
81. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 2002; 63: 1921–35.
82. Knowler WC, Barrett-Connor E, Fowler SE. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
83. Baron AD. Insulin resistance and vascular function. J Diabetes Complications 2002; 16: 92–102.
84. Palmer NO, Bakos HW, Owens JA et al. Diet and exercise in an obese mouse fed a high-fat diet improve metabolic health and reverse perturbed sperm function. Am J Physiol Endocrinol Metab 2012; 302 (7): 768–80.
85. Тюзиков И.А., Калинченко С.Ю., Ворслов Л.О., Тишова Ю.А. Мужское бесплодие и инсулинорезистентность: есть ли патогенетические связи, и кто, когда и как должен диагностировать и лечить их? Экспериментальная и клиническая урология. 2014; 2: 68-75. / Tiuzikov I.A., Kalinchenko S.Iu., Vorslov L.O., Tishova Iu.A. Muzhskoe besplodie i insulinorezistentnost': est' li patogeneticheskie sviazi, i kto, kogda i kak dolzhen diagnostirovat' i lechit' ikh? Eksperimental'naia i klinicheskaia urologiia. 2014; 2: 68-75. [in Russian]
86. Blaak E. Gender differences in fat metabolism. Curr Opin Clin Nutr Metab Care 2001; 4: 499–502.
87. Sarkar O, Bahrainwala J, Chandrasekaran S et al. Impact of inflammation on male fertility. Front Biosci (Elite Ed) 2011; 3: 89–95.
88. Tremellen K. Oxidative stress and male infertility – a clinical perspective. Hum Reprod Update 2008; 14 (3): 243–58.
89. McVary KT, Rademaker A, Lloyd GL et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 174 (4 Pt 1): 1327–33.
90. Sankhla M, Sharma TK, Mathur K et al. Relationship of oxidative stress with obesity and its role in obesity induced metabolic syndrome. Clin Lab 2012; 58 (5–6): 385–92.
91. Тюзиков И.А. Патология мужских половых органов как маркер сахарного диабета. Материалы пленума Российского общества урологов. Краснодар, 2010; с. 292. / Tiuzikov I.A. Patologiia muzhskikh polovykh organov kak marker sakharnogo diabeta. Materialy plenuma Rossiiskogo obshchestva urologov. Krasnodar, 2010; s. 292. [in Russian]
92. La Vignera S, Condorelli R, Vicari E et al. Diabetes mellitus and sperm parameters. J Androl 2012; 33 (2): 145–53.
93. Mallidis C, Czerwiec A, Filippi S et al. Spermatogenic and sperm quality differences in an experimental model of metabolic syndrome and hypogonadal hypogonadism. Reproduction 2011; 142 (1): 63–71.
94. Ворслов Л.О., Калинченко С.Ю., Гадзиева И.В. «Квартет здоровья» против «смертельного квартета». Часть первая: метаболическая невропатия, легко диагностировать, трудно лечить. Эффективная фармакотерапия. Урология. 2013; 1: 32–7. / Vorslov L.O., Kalinchenko S.Iu., Gadzieva I.V. «Kvartet zdorov'ia» protiv «smertel'nogo kvarteta». Chast' pervaia: metabolicheskaia nevropatiia, legko diagnostirovat', trudno lechit'. Effektivnaia farmakoterapiia. Urologiia. 2013; 1: 32–7. [in Russian]
95. Калинченко С.Ю., Ворслов Л.О., Курникова И.А., Гадзиева И.В. Современный взгляд на возможности применения альфа-липоевой кислоты. Эффективная фармакотерапия. Урология. 2012; 1: 2–8. / Kalinchenko S.Iu., Vorslov L.O., Kurnikova I.A., Gadzieva I.V. Sovremennyi vzgliad na vozmozhnosti primeneniia al'fa-lipoevoi kisloty. Effektivnaia farmakoterapiia. Urologiia. 2012; 1: 2–8. [in Russian]
96. Ворслов Л.О., Тишова Ю.А., Калинченко С.Ю. «Квартет здоровья» против «смертельного квартета». Часть вторая: дефицит тестостерона – стратегия проведения заместительной гормональной терапии. Эффективная фармакотерапия. Урология. 2013; 2: 18–22. / Vorslov L.O., Tishova Iu.A., Kalinchenko S.Iu. «Kvartet zdorov'ia» protiv «smertel'nogo kvarteta». Chast' vtoraia: defitsit testosterona – strategiia provedeniia zamestitel'noi gormonal'noi terapii. Effektivnaia farmakoterapiia. Urologiia. 2013; 2: 18–22. [in Russian]
97. Ивашкин В.Т., Драпкина О.М., Корнеева О.Н. Клинические варианты метаболического синдрома. М.: Медицинское информационное агентство, 2011. / Ivashkin V.T., Drapkina O.M., Korneeva O.N. Klinicheskie varianty metabolicheskogo sindroma. M.: Meditsinskoe informatsionnoe agentstvo, 2011. [in Russian]
98. Эндокринология. Национальное руководство. Под. ред. И.И.Дедова, Г.А.Мельниченко. М.: ГЭОТАР, 2013; с. 473; Демидова Т.Ю. Редуксин – новое средство решения старых проблем! Диабет. Образ жизни. 2007; 4: 4–7. / Endokrinologiia. Natsional'noe rukovodstvo. Pod. red. I.I.Dedova, G.A.Mel'nichenko. M.: GEOTAR, 2013; s. 473; Demidova T.Iu. Reduksin – novoe sredstvo resheniia starykh problem! Diabet. Obraz zhizni. 2007; 4: 4–7. [in Russian]
99. Романцова Т.И. Основные принципы регуляции энергетического баланса. Consilium Medicum. Эндокринология. 2014; 16 (4): 98. / Romantsova T.I. Osnovnye printsipy reguliatsii energeticheskogo balansa. Consilium Medicum. Endokrinologiia. 2014; 16 (4): 98. [in Russian]
100. Мельниченко Г.А., Романцова Т.И., Журавлева М.В. Всероссийская программа безопасного снижения веса «ПримаВера». Итоги первого года проведения. Ожирение и метаболизм. 2013; 4, 2013: 82. / Mel'nichenko G.A., Romantsova T.I., Zhuravleva M.V. Vserossiiskaia programma bezopasnogo snizheniia vesa «PrimaVera». Itogi pervogo goda provedeniia. Ozhirenie i metabolizm. 2013; 4, 2013: 82. [in Russian]
101. Бернштейн Л.М. Антидиабетический бугуанид метформин и онкологическая заболеваемость. Сахарный диабет. 2010; 3: 3–6. [in Russian]
102. Knowler WC, Barrett-Connor E, Fowler SE. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 33 (346): 393–403.
103. McNulty SJ et al. A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic Patients Treated With Metformin. Diabets care 2003; 26: 125.
104. Perrielo G, Misericordia P, Volpi E et al. Acute antihyperglycemic mechanism of metformini in NIDDM. Evidence of suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920–8.
105. Bannister CA, Holden SE, Jenkins-Jones S et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 2014; 16 (11): 1165–73.
106. Тюзиков И.А., Греков Е.А. Новая метаболическая концепция патогенеза идиопатического мужского бесплодия. Здравоохранение Таджикистана. 2011; 3: 392–4. / Tiuzikov I.A., Grekov E.A. Novaia metabolicheskaia kontseptsiia patogeneza idiopaticheskogo muzhskogo besplodiia. Zdravookhranenie Tadzhikistana. 2011; 3: 392–4. [in Russian]
107. Тюзиков И.А., Калинченко С.Ю., Мартов А.Г. Роль коррекции метаболического статуса при репродуктивных нарушениях у мужчин. Материалы X Всероссийского форума с международным участием «Мужское здоровье и долголетие». М., 2012; с. 95–6. / Tiuzikov I.A., Kalinchenko S.Iu., Martov A.G. Rol' korrektsii metabolicheskogo statusa pri reproduktivnykh narusheniiakh u muzhchin. Materialy X Vserossiiskogo foruma s mezhdunarodnym uchastiem «Muzhskoe zdorov'e i dolgoletie». M., 2012; s. 95–6. [in Russian]
108. Тюзиков И.А. Инсулинорезистентность и мужское бесплодие: диагностика и возможности медикаментозной коррекции. Материалы Всероссийcкой научно-практической конференции с международным участием «Рациональная фармакотерапия в урологии-2011». М., 2011; с. 148–9. / Tiuzikov I.A. Insulinorezistentnost' i muzhskoe besplodie: diagnostika i vozmozhnosti medikamentoznoi korrektsii. Materialy Vserossiickoi nauchno-prakticheskoi konferentsii s mezhdunarodnym uchastiem «Ratsional'naia farmakoterapiia v urologii-2011». M., 2011; s. 148–9. [in Russian]
109. Тюзиков И.А. Системная метаболическая терапия мужского бесплодия, ассоциированного с ожирением и инсулинорезистентностью. Материалы пленума Российского общества урологов. Кисловодск, 2011; с. 415–6. / Tiuzikov I.A. Sistemnaia metabolicheskaia terapiia muzhskogo besplodiia, assotsiirovannogo s ozhireniem i insulinorezistentnost'iu. Materialy plenuma Rossiiskogo obshchestva urologov. Kislovodsk, 2011; s. 415–6. [in Russian]
2. Predpolozhitel'naia chislennost' naseleniia Rossiiskoi Federatsii do 2025 goda. Ezhegodnyi spravochnik. M.: Federal'naia sluzhba gosudarstvennoi statistiki RF, 2005. [in Russian]
3. Chavarro JE, Toth TL, Wright DL et al. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril 2010; 93: 2222–31.
4. Hammoud AO, Wilde N, Gibson M et al. Male obesity and alteration in sperm parameters. Fertil Steril 2008; 90: 2222–5.
5. Crujeiras AB, Casanueva FF. Obesity and the reproductive system disorders: epigenetics as a potential bridge. Hum Reprod Update 2014. pii: dmu060. [Epub ahead of print]
6. Klenov VE, Jungheim ES. Obesity and reproductive function: a review of the evidence. Curr Opin Obstet Gynecol 2014; 26 (6): 455–60.
7. Gustafson B, Hammarstedt А, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2276–83.
8. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347–55.
9. Sánchez-Lara K, Morales-Graf L, Green D. Сancer and obesity. Cancer Causes Control 2011; 22 (2): 291–9.
10. Roitberg G.E. Metabolicheskii sindrom. M.: MEDpress-inform, 2007. [in Russian]
11. Kalinchenko S.Iu., Tishova Iu.A., Tiuzikov I.A., Vorslov L.O. Ozhirenie i metabolicheskii sindrom u muzhchin. M.: Prakticheskaia meditsina, 2014. [in Russian]
12. Pankov Iu.A. Zhirovaia tkan' kak endokrinnyi organ, reguliruiushchii rost, polovoe sozrevanie i drugie fiziologicheskie funktsii. Biokhimiia. 1999; 64: 601–9. [in Russian]
13. Lyon CJ et al. Mini-review: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195–200.
14. Könner AC, Brüning JC. Selective insulin and leptin resistance in metabolic disorders. Cell Metab 2012; 16 (2): 144–52.
15. Coppari R, Bjørbæk C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov 2012; 11 (9): 692–708.
16. Jung CH, Kim MS. Molecular mechanisms of central leptin resistance in obesity. Arch Pharm Res 2013; 36 (2): 201–7.
17. Paz-Filho G, Mastronardi C, Franco CB et al. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arq Bras Endocrinol Metab 2012; 56 (9): 597–607.
18. Roncavi DAK, van RLR. Promotion of human adipocite precursor replication by 17b-estradiol in culture. J Clin Invest 1977; 62: 503–8.
19. Dobs AS, Bachorik PS, Arver S et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab 2001; 86 (3): 1026–33.
20. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89 (6): 2548–56.
21. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.
22. American Diabetes association. Standards of medical care in diabetes. Diabetes Care 2008; 31: 12–54.
23. Shoelson SE, Herrero L, Naaz A. Obesity, Inflammation, and Insulin Resistance. Gastroenterology 2007; 132 (6): 2169–80.
24. Schmidt MI, Saad MJA, Duncan BB. Subclinical inflammation and obesity, diabetes and related disorders. Drug Discovery Today: Disease Mechanisms 2005; 2 (3): 307–12.
25. Kadowaki T, Yamauchi T, Kubota N et al. Role of adipokines in obesity-linked insulin resistance, metabolic syndrome and atherosclerosis. Atherosclerosis Suppl 2006; 7 (3): 164–70.
26. Astrup A, Finer N. Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'? Obes Rev 2000; 1 (2): 57–9.
27. Kalra S. Diabesity. J Pak Med Assoc 2013; 63 (4): 532–4; Bailey CJ. New therapies for diabesity. Curr Diab Rep 2009; 9 (5): 360–7.
28. Colagiuri S. Diabesity: therapeutic options. Diabetes Obes Metab 2010; 12 (6): 463–73.
29. Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med 2003; 41 (9): 1120–30.
30. Bozhedomov V.A., Gromenko D.S., Ushakova I.V. Prichiny oksidativnogo stressa spermatozoidov. Problemy reproduktsii. 2008; 6: 67–73. [in Russian]
31. Bozhedomov V.A., Gromenko D.S., Ushakova I.V. Oksidativnyi stress spermatozoidov v patogeneze muzhskogo besplodiia. Urologiia. 2009; 2: 51–6. [in Russian]
32. Villegas J, Schulz M, Soto L et al. Influence of reactive oxygen species produced by activated leukocytes at the level of apoptosis in mature human spermatozoa. Fertil Steril 2005; 83: 808–10.
33. Zorn B, Vidmar G, Meden-Vrtovec H. Seminal reactive oxygen species as predictors of fertilization, embryo quality and pregnancy rates after conventional in vitro fertilization and intracytoplasmic sperm injection. Int J Androl 2003; 26: 279–85.
34. Koppers AJ, Mitchell LA, Wang P et al. Phosphoinositide 3-kinase signalling pathway involvement in a truncated apoptotic cascade associated with motility loss and oxidative DNA damage in human spermatozoa. Biochem J 2011; 436 (3): 687–98.
35. Kemal Duru N, Morshedi M, Oehninger S. Effects of hydrogen peroxide on DNA and plasma membrane integrity of human spermatozoa. Fertil Steril 2000; 74: 1200–7.
36. Tremellen K. Oxidative stress and male infertility – a clinical perspective. Hum Reprod Update 2008; 14 (3): 243–58.
37. Showell MG, Brown J, Yazdani A et al. Antioxidants for male subfertility. Cochrane Database Syst Rev 2011; 1: CD007411.
38. Sarkar O, Bahrainwala J, Chandrasekaran S et al. Impact of inflammation on male fertility. Front Biosci (Elite Ed) 2011; 3: 89–95.
39. Eisenberg ML, Lipshultz LI. Varicocele-induced infertility: Newer insights into its pathophysiology. Indian J Urol 2011; 27 (1): 58–64.
40. Perez-Crespo M, Pintado B, Gutierrez-Adan A. Scrotal heat stress effects on sperm viability, sperm DNA integrity, and the offspring sex ratio in mice. Mol Reprod Dev 2007; 75: 40–7.
41. Kasturi SS, Tannir J, Brannigan RE. The metabolic syndrome and male infertility. J Androl 2008; 29: 251–9.
42. Brannian JD. Obesity and fertility S D Med 2011; 64 (7): 251–4.
43. Pasquali R, Patton L, Gambineri A. Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007; 14 (6): 482–7.
44. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic Syndrome and Urological Diseases Rev Urol 2010; 12 (4): 157–80.
45. Pasquali R, Patton L, Gambineri A. Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007; 14 (6): 482–7.
46. Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol 2010; 316 (2): 180–6.
47. Tiuzikov I.A. Metabolicheskii sindrom i muzhskoe besplodie. Andrologiia i genital'naia khirurgiia. 2013; 2: 5–10. [in Russian]
48. Stewart TM, Liu DY, Garrett C et al. Associations between andrological measures, hormones and semen quality in fertile Australian men: inverse relationship between obesity and sperm output. Hum Reprod 2009; 24: 1561–8.
49. Chavarro JE, Toth TL, Wright DL et al. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril 2010; 93: 2222–31.
50. Hammoud AO, Wilde N, Gibson M et al. Male obesity and alteration in sperm parameters. Fertil Steril 2008; 90: 2222–5.
51. Lee MJ, Fried SK. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab 2009; 296: 1230–8.
52. Luukkaa V, Pesonen U, Huhtaniemi I et al. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998; 83 (9): 3243–6.
53. Kapoor D, Clarke S, Stanworth R. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007; 156: 595–602.
54. Kalinchenko SY, Tishova YA, Rozhivanov RV, Mskhalaya GJ. Leptin and its negative influence on testosterone secretion in obese men with late onset hypogonadism. Presented at XVIII World Congress of the WAS, 1st World Congress for Sexual Health. April 15–19, 2007. Sydney, Australia. Abstract book 2007, OP1-12.
55. Goulis DG, Tarlatzis BC. Metabolic syndrome and reproduction: I. testicular function. Gynecol Endocrinol 2008; 24 (1): 33–9.
56. Pavlova Z.Sh., Tishova Iu.A., Kalinchenko S.Iu. i dr. Aktual'nye problemy XXI veka: muzhskoe besplodie, ozhirenie, defitsit vitamina D – est' li vzaimosviaz'? Moskovskii urolog. 2014; 6: 19–21. [in Russian]
57. Tiuzikov I.A. Gormon D-status u muzhchin s andrologicheskoi patologiei (pilotnoe issledovanie). Materialy Mezhdunarodnogo kongressa «Muzhskoe zdorov'e». Minsk, 2014; s. 90–2. [in Russian]
58. Tiuzikov I.A., Kalinchenko S.Iu., Vorslov L.O. Tishova Iu.A. Vitamin D, muzhskoe zdorov'e i muzhskaia reproduktsiia. Andrologiia i genital'naia khirurgiia. 2013; 4: 36–44. [in Russian]
59. Tiuzikov I.A., Kalinchenko S.Iu., Vorslov L.O. Tishova Iu.A. Vitamin D, muzhskoe zdorov'e i predstatel'naia zheleza (obzor literatury). Andrologiia i genital'naia khirurgiia. 2014; 3: 26–32. [in Russian]
60. Kalyani RR, Dobs AS. Androgen deficiency, diabetes and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007; 14: 226–34.
61. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003; 14: 281–7.
62. Weinberg JM. Lipotoxicity. Kidney Int 2006; 70 (9): 1560–6.
63. Aitken RJ, Krausz C. Oxidative stress, DNA damage and the Y chromosome. Reproduction 2001; 122: 497–506.
64. Garrido N, Meseguer M, Alvarez J et al. Relationship among standard semen parameters, glutathione peroxidase/glutathione reductase activity, and mRNA expression and reduced glutathione content in ejaculated spermatozoa from fertile and infertile men. Fertil Steril 2004; 82 (Suppl. 3): 1059–66.
65. Sarkar O, Bahrainwala J, Chandrasekaran S et al. Impact of inflammation on male fertility. Front Biosci (Elite Ed) 2011; 3: 89–95.
66. Nguyen RH, Wilcox AJ, Skaerven R et al. Men’s body mass index and infertility. Hum Reprod 2007; 22: 2488–93.
67. Ohwaki K, Endo F, Yano E. Relationship between body mass index and infertility in healthy male Japanese workers: a pilot study. Andrologia 2009; 41: 100–4.
68. Bener A, Al-Ansari AA, Zirie M et al. Is male fertility associated with type 2 diabetes mellitus? Int Urol Nephrol 2009; 41: 777–84.
69. Kort HI, Massey JB, Elsner CW et al. Impact of body mass index values on sperm quantity and quality. J Androl 2006; 27: 450–52.
70. Fejes I, Koloszár S, Szöllosi J et al. Is semen quality affected by male body fat distribution? Andrologia 2005; 37: 155–9.
71. Ali ST, Shaikh RN, Siddiqi AN et al. Semen analysis in insulin-dependent/noninsulin-dependent diabetic men with/without neuropathy. Arch Androl 1993; 30: 47–54.
72. Dohle GR, Diemer T, Giwercman A et al. Male Infertility Guideline. EAU, 2012.
73. Vinik AI, Maser RE, Mitchell BD et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553–79.
74. Gilja I, Parazajder J, Radej M et al. Retrograde ejaculation and loss of emission: possibilities of conservative treatment. Eur Urol 1994; 25: 226–8.
75. El-Sakka AI. Premature ejaculation in noninsulin- dependent diabetic patients. Int J Androl 2003; 26: 329–34.
76. Shiraishi K, Takihara H, Matsuyama H. Elevated scrotal temperature, but not varicocele grade, reflects testicular oxidative stress-mediated apoptosis. World J Urol 2010; 28: 359–64.
77. Tsao CW, Hsu CY, Chou YC et al. The relationship between varicoceles and obesity in a young adult population. Int J Androl 2009; 32: 385–90.
78. Handel LN, Shetty R, Sigman M. The relationship between varicoceles and obesity. J Urol 2006; 176: 2138–40.
79. Shafik A, Olfat S. Scrotal lipomatosis. Br J Urol 1981; 53: 50–4.
80. Shafik A, Olfat S. Lipectomy in the treatment of scrotal lipomatosis. Br J Urol 1981; 53: 55–61.
81. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 2002; 63: 1921–35.
82. Knowler WC, Barrett-Connor E, Fowler SE. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
83. Baron AD. Insulin resistance and vascular function. J Diabetes Complications 2002; 16: 92–102.
84. Palmer NO, Bakos HW, Owens JA et al. Diet and exercise in an obese mouse fed a high-fat diet improve metabolic health and reverse perturbed sperm function. Am J Physiol Endocrinol Metab 2012; 302 (7): 768–80.
85. Tiuzikov I.A., Kalinchenko S.Iu., Vorslov L.O., Tishova Iu.A. Muzhskoe besplodie i insulinorezistentnost': est' li patogeneticheskie sviazi, i kto, kogda i kak dolzhen diagnostirovat' i lechit' ikh? Eksperimental'naia i klinicheskaia urologiia. 2014; 2: 68-75. [in Russian]
86. Blaak E. Gender differences in fat metabolism. Curr Opin Clin Nutr Metab Care 2001; 4: 499–502.
87. Sarkar O, Bahrainwala J, Chandrasekaran S et al. Impact of inflammation on male fertility. Front Biosci (Elite Ed) 2011; 3: 89–95.
88. Tremellen K. Oxidative stress and male infertility – a clinical perspective. Hum Reprod Update 2008; 14 (3): 243–58.
89. McVary KT, Rademaker A, Lloyd GL et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 174 (4 Pt 1): 1327–33.
90. Sankhla M, Sharma TK, Mathur K et al. Relationship of oxidative stress with obesity and its role in obesity induced metabolic syndrome. Clin Lab 2012; 58 (5–6): 385–92.
91. Tiuzikov I.A. Patologiia muzhskikh polovykh organov kak marker sakharnogo diabeta. Materialy plenuma Rossiiskogo obshchestva urologov. Krasnodar, 2010; s. 292. [in Russian]
92. La Vignera S, Condorelli R, Vicari E et al. Diabetes mellitus and sperm parameters. J Androl 2012; 33 (2): 145–53.
93. Mallidis C, Czerwiec A, Filippi S et al. Spermatogenic and sperm quality differences in an experimental model of metabolic syndrome and hypogonadal hypogonadism. Reproduction 2011; 142 (1): 63–71.
94. Vorslov L.O., Kalinchenko S.Iu., Gadzieva I.V. «Kvartet zdorov'ia» protiv «smertel'nogo kvarteta». Chast' pervaia: metabolicheskaia nevropatiia, legko diagnostirovat', trudno lechit'. Effektivnaia farmakoterapiia. Urologiia. 2013; 1: 32–7. [in Russian]
95. Kalinchenko S.Iu., Vorslov L.O., Kurnikova I.A., Gadzieva I.V. Sovremennyi vzgliad na vozmozhnosti primeneniia al'fa-lipoevoi kisloty. Effektivnaia farmakoterapiia. Urologiia. 2012; 1: 2–8. [in Russian]
96. Vorslov L.O., Tishova Iu.A., Kalinchenko S.Iu. «Kvartet zdorov'ia» protiv «smertel'nogo kvarteta». Chast' vtoraia: defitsit testosterona – strategiia provedeniia zamestitel'noi gormonal'noi terapii. Effektivnaia farmakoterapiia. Urologiia. 2013; 2: 18–22. [in Russian]
97. Ivashkin V.T., Drapkina O.M., Korneeva O.N. Klinicheskie varianty metabolicheskogo sindroma. M.: Meditsinskoe informatsionnoe agentstvo, 2011. [in Russian]
98. Endokrinologiia. Natsional'noe rukovodstvo. Pod. red. I.I.Dedova, G.A.Mel'nichenko. M.: GEOTAR, 2013; s. 473; Demidova T.Iu. Reduksin – novoe sredstvo resheniia starykh problem! Diabet. Obraz zhizni. 2007; 4: 4–7. [in Russian]
99. Romantsova T.I. Osnovnye printsipy reguliatsii energeticheskogo balansa. Consilium Medicum. Endokrinologiia. 2014; 16 (4): 98. [in Russian]
100. Mel'nichenko G.A., Romantsova T.I., Zhuravleva M.V. Vserossiiskaia programma bezopasnogo snizheniia vesa «PrimaVera». Itogi pervogo goda provedeniia. Ozhirenie i metabolizm. 2013; 4, 2013: 82. [in Russian]
101. Бернштейн Л.М. Антидиабетический бугуанид метформин и онкологическая заболеваемость. Сахарный диабет. 2010; 3: 3–6. [in Russian]
102. Knowler WC, Barrett-Connor E, Fowler SE. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 33 (346): 393–403.
103. McNulty SJ et al. A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic Patients Treated With Metformin. Diabets care 2003; 26: 125.
104. Perrielo G, Misericordia P, Volpi E et al. Acute antihyperglycemic mechanism of metformini in NIDDM. Evidence of suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920–8.
105. Bannister CA, Holden SE, Jenkins-Jones S et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 2014; 16 (11): 1165–73.
106. Tiuzikov I.A., Grekov E.A. Novaia metabolicheskaia kontseptsiia patogeneza idiopaticheskogo muzhskogo besplodiia. Zdravookhranenie Tadzhikistana. 2011; 3: 392–4. [in Russian]
107. Tiuzikov I.A., Kalinchenko S.Iu., Martov A.G. Rol' korrektsii metabolicheskogo statusa pri reproduktivnykh narusheniiakh u muzhchin. Materialy X Vserossiiskogo foruma s mezhdunarodnym uchastiem «Muzhskoe zdorov'e i dolgoletie». M., 2012; s. 95–6. [in Russian]
108. Tiuzikov I.A. Insulinorezistentnost' i muzhskoe besplodie: diagnostika i vozmozhnosti medikamentoznoi korrektsii. Materialy Vserossiickoi nauchno-prakticheskoi konferentsii s mezhdunarodnym uchastiem «Ratsional'naia farmakoterapiia v urologii-2011». M., 2011; s. 148–9. [in Russian]
109. Tiuzikov I.A. Sistemnaia metabolicheskaia terapiia muzhskogo besplodiia, assotsiirovannogo s ozhireniem i insulinorezistentnost'iu. Materialy plenuma Rossiiskogo obshchestva urologov. Kislovodsk, 2011; s. 415–6. [in Russian]
2. Предположительная численность населения Российской Федерации до 2025 года. Ежегодный справочник. М.: Федеральная служба государственной статистики РФ, 2005. / Predpolozhitel'naia chislennost' naseleniia Rossiiskoi Federatsii do 2025 goda. Ezhegodnyi spravochnik. M.: Federal'naia sluzhba gosudarstvennoi statistiki RF, 2005. [in Russian]
3. Chavarro JE, Toth TL, Wright DL et al. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril 2010; 93: 2222–31.
4. Hammoud AO, Wilde N, Gibson M et al. Male obesity and alteration in sperm parameters. Fertil Steril 2008; 90: 2222–5.
5. Crujeiras AB, Casanueva FF. Obesity and the reproductive system disorders: epigenetics as a potential bridge. Hum Reprod Update 2014. pii: dmu060. [Epub ahead of print]
6. Klenov VE, Jungheim ES. Obesity and reproductive function: a review of the evidence. Curr Opin Obstet Gynecol 2014; 26 (6): 455–60.
7. Gustafson B, Hammarstedt А, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2276–83.
8. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347–55.
9. Sánchez-Lara K, Morales-Graf L, Green D. Сancer and obesity. Cancer Causes Control 2011; 22 (2): 291–9.
10. Ройтберг Г.Е. Метаболический синдром. М.: МЕДпресс-информ, 2007. / Roitberg G.E. Metabolicheskii sindrom. M.: MEDpress-inform, 2007. [in Russian]
11. Калинченко С.Ю., Тишова Ю.А., Тюзиков И.А., Ворслов Л.О. Ожирение и метаболический синдром у мужчин. М.: Практическая медицина, 2014. / Kalinchenko S.Iu., Tishova Iu.A., Tiuzikov I.A., Vorslov L.O. Ozhirenie i metabolicheskii sindrom u muzhchin. M.: Prakticheskaia meditsina, 2014. [in Russian]
12. Панков Ю.А. Жировая ткань как эндокринный орган, регулирующий рост, половое созревание и другие физиологические функции. Биохимия. 1999; 64: 601–9. / Pankov Iu.A. Zhirovaia tkan' kak endokrinnyi organ, reguliruiushchii rost, polovoe sozrevanie i drugie fiziologicheskie funktsii. Biokhimiia. 1999; 64: 601–9. [in Russian]
13. Lyon CJ et al. Mini-review: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195–200.
14. Könner AC, Brüning JC. Selective insulin and leptin resistance in metabolic disorders. Cell Metab 2012; 16 (2): 144–52.
15. Coppari R, Bjørbæk C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov 2012; 11 (9): 692–708.
16. Jung CH, Kim MS. Molecular mechanisms of central leptin resistance in obesity. Arch Pharm Res 2013; 36 (2): 201–7.
17. Paz-Filho G, Mastronardi C, Franco CB et al. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arq Bras Endocrinol Metab 2012; 56 (9): 597–607.
18. Roncavi DAK, van RLR. Promotion of human adipocite precursor replication by 17b-estradiol in culture. J Clin Invest 1977; 62: 503–8.
19. Dobs AS, Bachorik PS, Arver S et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab 2001; 86 (3): 1026–33.
20. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89 (6): 2548–56.
21. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.
22. American Diabetes association. Standards of medical care in diabetes. Diabetes Care 2008; 31: 12–54.
23. Shoelson SE, Herrero L, Naaz A. Obesity, Inflammation, and Insulin Resistance. Gastroenterology 2007; 132 (6): 2169–80.
24. Schmidt MI, Saad MJA, Duncan BB. Subclinical inflammation and obesity, diabetes and related disorders. Drug Discovery Today: Disease Mechanisms 2005; 2 (3): 307–12.
25. Kadowaki T, Yamauchi T, Kubota N et al. Role of adipokines in obesity-linked insulin resistance, metabolic syndrome and atherosclerosis. Atherosclerosis Suppl 2006; 7 (3): 164–70.
26. Astrup A, Finer N. Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'? Obes Rev 2000; 1 (2): 57–9.
27. Kalra S. Diabesity. J Pak Med Assoc 2013; 63 (4): 532–4; Bailey CJ. New therapies for diabesity. Curr Diab Rep 2009; 9 (5): 360–7.
28. Colagiuri S. Diabesity: therapeutic options. Diabetes Obes Metab 2010; 12 (6): 463–73.
29. Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med 2003; 41 (9): 1120–30.
30. Божедомов В.А., Громенко Д.С., Ушакова И.В. Причины оксидативного стресса сперматозоидов. Проблемы репродукции. 2008; 6: 67–73. / Bozhedomov V.A., Gromenko D.S., Ushakova I.V. Prichiny oksidativnogo stressa spermatozoidov. Problemy reproduktsii. 2008; 6: 67–73. [in Russian]
31. Божедомов В.А., Громенко Д.С., Ушакова И.В. Оксидативный стресс сперматозоидов в патогенезе мужского бесплодия. Урология. 2009; 2: 51–6. / Bozhedomov V.A., Gromenko D.S., Ushakova I.V. Oksidativnyi stress spermatozoidov v patogeneze muzhskogo besplodiia. Urologiia. 2009; 2: 51–6. [in Russian]
32. Villegas J, Schulz M, Soto L et al. Influence of reactive oxygen species produced by activated leukocytes at the level of apoptosis in mature human spermatozoa. Fertil Steril 2005; 83: 808–10.
33. Zorn B, Vidmar G, Meden-Vrtovec H. Seminal reactive oxygen species as predictors of fertilization, embryo quality and pregnancy rates after conventional in vitro fertilization and intracytoplasmic sperm injection. Int J Androl 2003; 26: 279–85.
34. Koppers AJ, Mitchell LA, Wang P et al. Phosphoinositide 3-kinase signalling pathway involvement in a truncated apoptotic cascade associated with motility loss and oxidative DNA damage in human spermatozoa. Biochem J 2011; 436 (3): 687–98.
35. Kemal Duru N, Morshedi M, Oehninger S. Effects of hydrogen peroxide on DNA and plasma membrane integrity of human spermatozoa. Fertil Steril 2000; 74: 1200–7.
36. Tremellen K. Oxidative stress and male infertility – a clinical perspective. Hum Reprod Update 2008; 14 (3): 243–58.
37. Showell MG, Brown J, Yazdani A et al. Antioxidants for male subfertility. Cochrane Database Syst Rev 2011; 1: CD007411.
38. Sarkar O, Bahrainwala J, Chandrasekaran S et al. Impact of inflammation on male fertility. Front Biosci (Elite Ed) 2011; 3: 89–95.
39. Eisenberg ML, Lipshultz LI. Varicocele-induced infertility: Newer insights into its pathophysiology. Indian J Urol 2011; 27 (1): 58–64.
40. Perez-Crespo M, Pintado B, Gutierrez-Adan A. Scrotal heat stress effects on sperm viability, sperm DNA integrity, and the offspring sex ratio in mice. Mol Reprod Dev 2007; 75: 40–7.
41. Kasturi SS, Tannir J, Brannigan RE. The metabolic syndrome and male infertility. J Androl 2008; 29: 251–9.
42. Brannian JD. Obesity and fertility S D Med 2011; 64 (7): 251–4.
43. Pasquali R, Patton L, Gambineri A. Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007; 14 (6): 482–7.
44. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic Syndrome and Urological Diseases Rev Urol 2010; 12 (4): 157–80.
45. Pasquali R, Patton L, Gambineri A. Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007; 14 (6): 482–7.
46. Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol 2010; 316 (2): 180–6.
47. Тюзиков И.А. Метаболический синдром и мужское бесплодие. Андрология и генитальная хирургия. 2013; 2: 5–10. / Tiuzikov I.A. Metabolicheskii sindrom i muzhskoe besplodie. Andrologiia i genital'naia khirurgiia. 2013; 2: 5–10. [in Russian]
48. Stewart TM, Liu DY, Garrett C et al. Associations between andrological measures, hormones and semen quality in fertile Australian men: inverse relationship between obesity and sperm output. Hum Reprod 2009; 24: 1561–8.
49. Chavarro JE, Toth TL, Wright DL et al. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril 2010; 93: 2222–31.
50. Hammoud AO, Wilde N, Gibson M et al. Male obesity and alteration in sperm parameters. Fertil Steril 2008; 90: 2222–5.
51. Lee MJ, Fried SK. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab 2009; 296: 1230–8.
52. Luukkaa V, Pesonen U, Huhtaniemi I et al. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998; 83 (9): 3243–6.
53. Kapoor D, Clarke S, Stanworth R. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007; 156: 595–602.
54. Kalinchenko SY, Tishova YA, Rozhivanov RV, Mskhalaya GJ. Leptin and its negative influence on testosterone secretion in obese men with late onset hypogonadism. Presented at XVIII World Congress of the WAS, 1st World Congress for Sexual Health. April 15–19, 2007. Sydney, Australia. Abstract book 2007, OP1-12.
55. Goulis DG, Tarlatzis BC. Metabolic syndrome and reproduction: I. testicular function. Gynecol Endocrinol 2008; 24 (1): 33–9.
56. Павлова З.Ш., Тишова Ю.А., Калинченко С.Ю. и др. Актуальные проблемы XXI века: мужское бесплодие, ожирение, дефицит витамина D – есть ли взаимосвязь? Московский уролог. 2014; 6: 19–21. / Pavlova Z.Sh., Tishova Iu.A., Kalinchenko S.Iu. i dr. Aktual'nye problemy XXI veka: muzhskoe besplodie, ozhirenie, defitsit vitamina D – est' li vzaimosviaz'? Moskovskii urolog. 2014; 6: 19–21. [in Russian]
57. Тюзиков И.А. Гормон D-статус у мужчин с андрологической патологией (пилотное исследование). Материалы Международного конгресса «Мужское здоровье». Минск, 2014; с. 90–2. / Tiuzikov I.A. Gormon D-status u muzhchin s andrologicheskoi patologiei (pilotnoe issledovanie). Materialy Mezhdunarodnogo kongressa «Muzhskoe zdorov'e». Minsk, 2014; s. 90–2. [in Russian]
58. Тюзиков И.А., Калинченко С.Ю., Ворслов Л.О. Тишова Ю.А. Витамин D, мужское здоровье и мужская репродукция. Андрология и генитальная хирургия. 2013; 4: 36–44. / Tiuzikov I.A., Kalinchenko S.Iu., Vorslov L.O. Tishova Iu.A. Vitamin D, muzhskoe zdorov'e i muzhskaia reproduktsiia. Andrologiia i genital'naia khirurgiia. 2013; 4: 36–44. [in Russian]
59. Тюзиков И.А., Калинченко С.Ю., Ворслов Л.О. Тишова Ю.А. Витамин D, мужское здоровье и предстательная железа (обзор литературы). Андрология и генитальная хирургия. 2014; 3: 26–32. / Tiuzikov I.A., Kalinchenko S.Iu., Vorslov L.O. Tishova Iu.A. Vitamin D, muzhskoe zdorov'e i predstatel'naia zheleza (obzor literatury). Andrologiia i genital'naia khirurgiia. 2014; 3: 26–32. [in Russian]
60. Kalyani RR, Dobs AS. Androgen deficiency, diabetes and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007; 14: 226–34.
61. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003; 14: 281–7.
62. Weinberg JM. Lipotoxicity. Kidney Int 2006; 70 (9): 1560–6.
63. Aitken RJ, Krausz C. Oxidative stress, DNA damage and the Y chromosome. Reproduction 2001; 122: 497–506.
64. Garrido N, Meseguer M, Alvarez J et al. Relationship among standard semen parameters, glutathione peroxidase/glutathione reductase activity, and mRNA expression and reduced glutathione content in ejaculated spermatozoa from fertile and infertile men. Fertil Steril 2004; 82 (Suppl. 3): 1059–66.
65. Sarkar O, Bahrainwala J, Chandrasekaran S et al. Impact of inflammation on male fertility. Front Biosci (Elite Ed) 2011; 3: 89–95.
66. Nguyen RH, Wilcox AJ, Skaerven R et al. Men’s body mass index and infertility. Hum Reprod 2007; 22: 2488–93.
67. Ohwaki K, Endo F, Yano E. Relationship between body mass index and infertility in healthy male Japanese workers: a pilot study. Andrologia 2009; 41: 100–4.
68. Bener A, Al-Ansari AA, Zirie M et al. Is male fertility associated with type 2 diabetes mellitus? Int Urol Nephrol 2009; 41: 777–84.
69. Kort HI, Massey JB, Elsner CW et al. Impact of body mass index values on sperm quantity and quality. J Androl 2006; 27: 450–52.
70. Fejes I, Koloszár S, Szöllosi J et al. Is semen quality affected by male body fat distribution? Andrologia 2005; 37: 155–9.
71. Ali ST, Shaikh RN, Siddiqi AN et al. Semen analysis in insulin-dependent/noninsulin-dependent diabetic men with/without neuropathy. Arch Androl 1993; 30: 47–54.
72. Dohle GR, Diemer T, Giwercman A et al. Male Infertility Guideline. EAU, 2012.
73. Vinik AI, Maser RE, Mitchell BD et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553–79.
74. Gilja I, Parazajder J, Radej M et al. Retrograde ejaculation and loss of emission: possibilities of conservative treatment. Eur Urol 1994; 25: 226–8.
75. El-Sakka AI. Premature ejaculation in noninsulin- dependent diabetic patients. Int J Androl 2003; 26: 329–34.
76. Shiraishi K, Takihara H, Matsuyama H. Elevated scrotal temperature, but not varicocele grade, reflects testicular oxidative stress-mediated apoptosis. World J Urol 2010; 28: 359–64.
77. Tsao CW, Hsu CY, Chou YC et al. The relationship between varicoceles and obesity in a young adult population. Int J Androl 2009; 32: 385–90.
78. Handel LN, Shetty R, Sigman M. The relationship between varicoceles and obesity. J Urol 2006; 176: 2138–40.
79. Shafik A, Olfat S. Scrotal lipomatosis. Br J Urol 1981; 53: 50–4.
80. Shafik A, Olfat S. Lipectomy in the treatment of scrotal lipomatosis. Br J Urol 1981; 53: 55–61.
81. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 2002; 63: 1921–35.
82. Knowler WC, Barrett-Connor E, Fowler SE. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
83. Baron AD. Insulin resistance and vascular function. J Diabetes Complications 2002; 16: 92–102.
84. Palmer NO, Bakos HW, Owens JA et al. Diet and exercise in an obese mouse fed a high-fat diet improve metabolic health and reverse perturbed sperm function. Am J Physiol Endocrinol Metab 2012; 302 (7): 768–80.
85. Тюзиков И.А., Калинченко С.Ю., Ворслов Л.О., Тишова Ю.А. Мужское бесплодие и инсулинорезистентность: есть ли патогенетические связи, и кто, когда и как должен диагностировать и лечить их? Экспериментальная и клиническая урология. 2014; 2: 68-75. / Tiuzikov I.A., Kalinchenko S.Iu., Vorslov L.O., Tishova Iu.A. Muzhskoe besplodie i insulinorezistentnost': est' li patogeneticheskie sviazi, i kto, kogda i kak dolzhen diagnostirovat' i lechit' ikh? Eksperimental'naia i klinicheskaia urologiia. 2014; 2: 68-75. [in Russian]
86. Blaak E. Gender differences in fat metabolism. Curr Opin Clin Nutr Metab Care 2001; 4: 499–502.
87. Sarkar O, Bahrainwala J, Chandrasekaran S et al. Impact of inflammation on male fertility. Front Biosci (Elite Ed) 2011; 3: 89–95.
88. Tremellen K. Oxidative stress and male infertility – a clinical perspective. Hum Reprod Update 2008; 14 (3): 243–58.
89. McVary KT, Rademaker A, Lloyd GL et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 174 (4 Pt 1): 1327–33.
90. Sankhla M, Sharma TK, Mathur K et al. Relationship of oxidative stress with obesity and its role in obesity induced metabolic syndrome. Clin Lab 2012; 58 (5–6): 385–92.
91. Тюзиков И.А. Патология мужских половых органов как маркер сахарного диабета. Материалы пленума Российского общества урологов. Краснодар, 2010; с. 292. / Tiuzikov I.A. Patologiia muzhskikh polovykh organov kak marker sakharnogo diabeta. Materialy plenuma Rossiiskogo obshchestva urologov. Krasnodar, 2010; s. 292. [in Russian]
92. La Vignera S, Condorelli R, Vicari E et al. Diabetes mellitus and sperm parameters. J Androl 2012; 33 (2): 145–53.
93. Mallidis C, Czerwiec A, Filippi S et al. Spermatogenic and sperm quality differences in an experimental model of metabolic syndrome and hypogonadal hypogonadism. Reproduction 2011; 142 (1): 63–71.
94. Ворслов Л.О., Калинченко С.Ю., Гадзиева И.В. «Квартет здоровья» против «смертельного квартета». Часть первая: метаболическая невропатия, легко диагностировать, трудно лечить. Эффективная фармакотерапия. Урология. 2013; 1: 32–7. / Vorslov L.O., Kalinchenko S.Iu., Gadzieva I.V. «Kvartet zdorov'ia» protiv «smertel'nogo kvarteta». Chast' pervaia: metabolicheskaia nevropatiia, legko diagnostirovat', trudno lechit'. Effektivnaia farmakoterapiia. Urologiia. 2013; 1: 32–7. [in Russian]
95. Калинченко С.Ю., Ворслов Л.О., Курникова И.А., Гадзиева И.В. Современный взгляд на возможности применения альфа-липоевой кислоты. Эффективная фармакотерапия. Урология. 2012; 1: 2–8. / Kalinchenko S.Iu., Vorslov L.O., Kurnikova I.A., Gadzieva I.V. Sovremennyi vzgliad na vozmozhnosti primeneniia al'fa-lipoevoi kisloty. Effektivnaia farmakoterapiia. Urologiia. 2012; 1: 2–8. [in Russian]
96. Ворслов Л.О., Тишова Ю.А., Калинченко С.Ю. «Квартет здоровья» против «смертельного квартета». Часть вторая: дефицит тестостерона – стратегия проведения заместительной гормональной терапии. Эффективная фармакотерапия. Урология. 2013; 2: 18–22. / Vorslov L.O., Tishova Iu.A., Kalinchenko S.Iu. «Kvartet zdorov'ia» protiv «smertel'nogo kvarteta». Chast' vtoraia: defitsit testosterona – strategiia provedeniia zamestitel'noi gormonal'noi terapii. Effektivnaia farmakoterapiia. Urologiia. 2013; 2: 18–22. [in Russian]
97. Ивашкин В.Т., Драпкина О.М., Корнеева О.Н. Клинические варианты метаболического синдрома. М.: Медицинское информационное агентство, 2011. / Ivashkin V.T., Drapkina O.M., Korneeva O.N. Klinicheskie varianty metabolicheskogo sindroma. M.: Meditsinskoe informatsionnoe agentstvo, 2011. [in Russian]
98. Эндокринология. Национальное руководство. Под. ред. И.И.Дедова, Г.А.Мельниченко. М.: ГЭОТАР, 2013; с. 473; Демидова Т.Ю. Редуксин – новое средство решения старых проблем! Диабет. Образ жизни. 2007; 4: 4–7. / Endokrinologiia. Natsional'noe rukovodstvo. Pod. red. I.I.Dedova, G.A.Mel'nichenko. M.: GEOTAR, 2013; s. 473; Demidova T.Iu. Reduksin – novoe sredstvo resheniia starykh problem! Diabet. Obraz zhizni. 2007; 4: 4–7. [in Russian]
99. Романцова Т.И. Основные принципы регуляции энергетического баланса. Consilium Medicum. Эндокринология. 2014; 16 (4): 98. / Romantsova T.I. Osnovnye printsipy reguliatsii energeticheskogo balansa. Consilium Medicum. Endokrinologiia. 2014; 16 (4): 98. [in Russian]
100. Мельниченко Г.А., Романцова Т.И., Журавлева М.В. Всероссийская программа безопасного снижения веса «ПримаВера». Итоги первого года проведения. Ожирение и метаболизм. 2013; 4, 2013: 82. / Mel'nichenko G.A., Romantsova T.I., Zhuravleva M.V. Vserossiiskaia programma bezopasnogo snizheniia vesa «PrimaVera». Itogi pervogo goda provedeniia. Ozhirenie i metabolizm. 2013; 4, 2013: 82. [in Russian]
101. Бернштейн Л.М. Антидиабетический бугуанид метформин и онкологическая заболеваемость. Сахарный диабет. 2010; 3: 3–6. [in Russian]
102. Knowler WC, Barrett-Connor E, Fowler SE. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 33 (346): 393–403.
103. McNulty SJ et al. A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic Patients Treated With Metformin. Diabets care 2003; 26: 125.
104. Perrielo G, Misericordia P, Volpi E et al. Acute antihyperglycemic mechanism of metformini in NIDDM. Evidence of suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920–8.
105. Bannister CA, Holden SE, Jenkins-Jones S et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 2014; 16 (11): 1165–73.
106. Тюзиков И.А., Греков Е.А. Новая метаболическая концепция патогенеза идиопатического мужского бесплодия. Здравоохранение Таджикистана. 2011; 3: 392–4. / Tiuzikov I.A., Grekov E.A. Novaia metabolicheskaia kontseptsiia patogeneza idiopaticheskogo muzhskogo besplodiia. Zdravookhranenie Tadzhikistana. 2011; 3: 392–4. [in Russian]
107. Тюзиков И.А., Калинченко С.Ю., Мартов А.Г. Роль коррекции метаболического статуса при репродуктивных нарушениях у мужчин. Материалы X Всероссийского форума с международным участием «Мужское здоровье и долголетие». М., 2012; с. 95–6. / Tiuzikov I.A., Kalinchenko S.Iu., Martov A.G. Rol' korrektsii metabolicheskogo statusa pri reproduktivnykh narusheniiakh u muzhchin. Materialy X Vserossiiskogo foruma s mezhdunarodnym uchastiem «Muzhskoe zdorov'e i dolgoletie». M., 2012; s. 95–6. [in Russian]
108. Тюзиков И.А. Инсулинорезистентность и мужское бесплодие: диагностика и возможности медикаментозной коррекции. Материалы Всероссийcкой научно-практической конференции с международным участием «Рациональная фармакотерапия в урологии-2011». М., 2011; с. 148–9. / Tiuzikov I.A. Insulinorezistentnost' i muzhskoe besplodie: diagnostika i vozmozhnosti medikamentoznoi korrektsii. Materialy Vserossiickoi nauchno-prakticheskoi konferentsii s mezhdunarodnym uchastiem «Ratsional'naia farmakoterapiia v urologii-2011». M., 2011; s. 148–9. [in Russian]
109. Тюзиков И.А. Системная метаболическая терапия мужского бесплодия, ассоциированного с ожирением и инсулинорезистентностью. Материалы пленума Российского общества урологов. Кисловодск, 2011; с. 415–6. / Tiuzikov I.A. Sistemnaia metabolicheskaia terapiia muzhskogo besplodiia, assotsiirovannogo s ozhireniem i insulinorezistentnost'iu. Materialy plenuma Rossiiskogo obshchestva urologov. Kislovodsk, 2011; s. 415–6. [in Russian]
________________________________________________
2. Predpolozhitel'naia chislennost' naseleniia Rossiiskoi Federatsii do 2025 goda. Ezhegodnyi spravochnik. M.: Federal'naia sluzhba gosudarstvennoi statistiki RF, 2005. [in Russian]
3. Chavarro JE, Toth TL, Wright DL et al. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril 2010; 93: 2222–31.
4. Hammoud AO, Wilde N, Gibson M et al. Male obesity and alteration in sperm parameters. Fertil Steril 2008; 90: 2222–5.
5. Crujeiras AB, Casanueva FF. Obesity and the reproductive system disorders: epigenetics as a potential bridge. Hum Reprod Update 2014. pii: dmu060. [Epub ahead of print]
6. Klenov VE, Jungheim ES. Obesity and reproductive function: a review of the evidence. Curr Opin Obstet Gynecol 2014; 26 (6): 455–60.
7. Gustafson B, Hammarstedt А, Andersson CX, Smith U. Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol 2007; 27: 2276–83.
8. Trayhurn P, Wood IS. Adipokines: inflammation and the pleiotropic role of white adipose tissue. Br J Nutr 2004; 92: 347–55.
9. Sánchez-Lara K, Morales-Graf L, Green D. Сancer and obesity. Cancer Causes Control 2011; 22 (2): 291–9.
10. Roitberg G.E. Metabolicheskii sindrom. M.: MEDpress-inform, 2007. [in Russian]
11. Kalinchenko S.Iu., Tishova Iu.A., Tiuzikov I.A., Vorslov L.O. Ozhirenie i metabolicheskii sindrom u muzhchin. M.: Prakticheskaia meditsina, 2014. [in Russian]
12. Pankov Iu.A. Zhirovaia tkan' kak endokrinnyi organ, reguliruiushchii rost, polovoe sozrevanie i drugie fiziologicheskie funktsii. Biokhimiia. 1999; 64: 601–9. [in Russian]
13. Lyon CJ et al. Mini-review: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195–200.
14. Könner AC, Brüning JC. Selective insulin and leptin resistance in metabolic disorders. Cell Metab 2012; 16 (2): 144–52.
15. Coppari R, Bjørbæk C. Leptin revisited: its mechanism of action and potential for treating diabetes. Nat Rev Drug Discov 2012; 11 (9): 692–708.
16. Jung CH, Kim MS. Molecular mechanisms of central leptin resistance in obesity. Arch Pharm Res 2013; 36 (2): 201–7.
17. Paz-Filho G, Mastronardi C, Franco CB et al. Leptin: molecular mechanisms, systemic pro-inflammatory effects, and clinical implications. Arq Bras Endocrinol Metab 2012; 56 (9): 597–607.
18. Roncavi DAK, van RLR. Promotion of human adipocite precursor replication by 17b-estradiol in culture. J Clin Invest 1977; 62: 503–8.
19. Dobs AS, Bachorik PS, Arver S et al. Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system. J Clin Endocrinol Metab 2001; 86 (3): 1026–33.
20. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89 (6): 2548–56.
21. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595–607.
22. American Diabetes association. Standards of medical care in diabetes. Diabetes Care 2008; 31: 12–54.
23. Shoelson SE, Herrero L, Naaz A. Obesity, Inflammation, and Insulin Resistance. Gastroenterology 2007; 132 (6): 2169–80.
24. Schmidt MI, Saad MJA, Duncan BB. Subclinical inflammation and obesity, diabetes and related disorders. Drug Discovery Today: Disease Mechanisms 2005; 2 (3): 307–12.
25. Kadowaki T, Yamauchi T, Kubota N et al. Role of adipokines in obesity-linked insulin resistance, metabolic syndrome and atherosclerosis. Atherosclerosis Suppl 2006; 7 (3): 164–70.
26. Astrup A, Finer N. Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'? Obes Rev 2000; 1 (2): 57–9.
27. Kalra S. Diabesity. J Pak Med Assoc 2013; 63 (4): 532–4; Bailey CJ. New therapies for diabesity. Curr Diab Rep 2009; 9 (5): 360–7.
28. Colagiuri S. Diabesity: therapeutic options. Diabetes Obes Metab 2010; 12 (6): 463–73.
29. Schmidt MI, Duncan BB. Diabesity: an inflammatory metabolic condition. Clin Chem Lab Med 2003; 41 (9): 1120–30.
30. Bozhedomov V.A., Gromenko D.S., Ushakova I.V. Prichiny oksidativnogo stressa spermatozoidov. Problemy reproduktsii. 2008; 6: 67–73. [in Russian]
31. Bozhedomov V.A., Gromenko D.S., Ushakova I.V. Oksidativnyi stress spermatozoidov v patogeneze muzhskogo besplodiia. Urologiia. 2009; 2: 51–6. [in Russian]
32. Villegas J, Schulz M, Soto L et al. Influence of reactive oxygen species produced by activated leukocytes at the level of apoptosis in mature human spermatozoa. Fertil Steril 2005; 83: 808–10.
33. Zorn B, Vidmar G, Meden-Vrtovec H. Seminal reactive oxygen species as predictors of fertilization, embryo quality and pregnancy rates after conventional in vitro fertilization and intracytoplasmic sperm injection. Int J Androl 2003; 26: 279–85.
34. Koppers AJ, Mitchell LA, Wang P et al. Phosphoinositide 3-kinase signalling pathway involvement in a truncated apoptotic cascade associated with motility loss and oxidative DNA damage in human spermatozoa. Biochem J 2011; 436 (3): 687–98.
35. Kemal Duru N, Morshedi M, Oehninger S. Effects of hydrogen peroxide on DNA and plasma membrane integrity of human spermatozoa. Fertil Steril 2000; 74: 1200–7.
36. Tremellen K. Oxidative stress and male infertility – a clinical perspective. Hum Reprod Update 2008; 14 (3): 243–58.
37. Showell MG, Brown J, Yazdani A et al. Antioxidants for male subfertility. Cochrane Database Syst Rev 2011; 1: CD007411.
38. Sarkar O, Bahrainwala J, Chandrasekaran S et al. Impact of inflammation on male fertility. Front Biosci (Elite Ed) 2011; 3: 89–95.
39. Eisenberg ML, Lipshultz LI. Varicocele-induced infertility: Newer insights into its pathophysiology. Indian J Urol 2011; 27 (1): 58–64.
40. Perez-Crespo M, Pintado B, Gutierrez-Adan A. Scrotal heat stress effects on sperm viability, sperm DNA integrity, and the offspring sex ratio in mice. Mol Reprod Dev 2007; 75: 40–7.
41. Kasturi SS, Tannir J, Brannigan RE. The metabolic syndrome and male infertility. J Androl 2008; 29: 251–9.
42. Brannian JD. Obesity and fertility S D Med 2011; 64 (7): 251–4.
43. Pasquali R, Patton L, Gambineri A. Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007; 14 (6): 482–7.
44. Gorbachinsky I, Akpinar H, Assimos DG. Metabolic Syndrome and Urological Diseases Rev Urol 2010; 12 (4): 157–80.
45. Pasquali R, Patton L, Gambineri A. Obesity and infertility. Curr Opin Endocrinol Diabetes Obes 2007; 14 (6): 482–7.
46. Mah PM, Wittert GA. Obesity and testicular function. Mol Cell Endocrinol 2010; 316 (2): 180–6.
47. Tiuzikov I.A. Metabolicheskii sindrom i muzhskoe besplodie. Andrologiia i genital'naia khirurgiia. 2013; 2: 5–10. [in Russian]
48. Stewart TM, Liu DY, Garrett C et al. Associations between andrological measures, hormones and semen quality in fertile Australian men: inverse relationship between obesity and sperm output. Hum Reprod 2009; 24: 1561–8.
49. Chavarro JE, Toth TL, Wright DL et al. Body mass index in relation to semen quality, sperm DNA integrity, and serum reproductive hormone levels among men attending an infertility clinic. Fertil Steril 2010; 93: 2222–31.
50. Hammoud AO, Wilde N, Gibson M et al. Male obesity and alteration in sperm parameters. Fertil Steril 2008; 90: 2222–5.
51. Lee MJ, Fried SK. Integration of hormonal and nutrient signals that regulate leptin synthesis and secretion. Am J Physiol Endocrinol Metab 2009; 296: 1230–8.
52. Luukkaa V, Pesonen U, Huhtaniemi I et al. Inverse correlation between serum testosterone and leptin in men. J Clin Endocrinol Metab 1998; 83 (9): 3243–6.
53. Kapoor D, Clarke S, Stanworth R. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007; 156: 595–602.
54. Kalinchenko SY, Tishova YA, Rozhivanov RV, Mskhalaya GJ. Leptin and its negative influence on testosterone secretion in obese men with late onset hypogonadism. Presented at XVIII World Congress of the WAS, 1st World Congress for Sexual Health. April 15–19, 2007. Sydney, Australia. Abstract book 2007, OP1-12.
55. Goulis DG, Tarlatzis BC. Metabolic syndrome and reproduction: I. testicular function. Gynecol Endocrinol 2008; 24 (1): 33–9.
56. Pavlova Z.Sh., Tishova Iu.A., Kalinchenko S.Iu. i dr. Aktual'nye problemy XXI veka: muzhskoe besplodie, ozhirenie, defitsit vitamina D – est' li vzaimosviaz'? Moskovskii urolog. 2014; 6: 19–21. [in Russian]
57. Tiuzikov I.A. Gormon D-status u muzhchin s andrologicheskoi patologiei (pilotnoe issledovanie). Materialy Mezhdunarodnogo kongressa «Muzhskoe zdorov'e». Minsk, 2014; s. 90–2. [in Russian]
58. Tiuzikov I.A., Kalinchenko S.Iu., Vorslov L.O. Tishova Iu.A. Vitamin D, muzhskoe zdorov'e i muzhskaia reproduktsiia. Andrologiia i genital'naia khirurgiia. 2013; 4: 36–44. [in Russian]
59. Tiuzikov I.A., Kalinchenko S.Iu., Vorslov L.O. Tishova Iu.A. Vitamin D, muzhskoe zdorov'e i predstatel'naia zheleza (obzor literatury). Andrologiia i genital'naia khirurgiia. 2014; 3: 26–32. [in Russian]
60. Kalyani RR, Dobs AS. Androgen deficiency, diabetes and the metabolic syndrome in men. Curr Opin Endocrinol Diabetes Obes 2007; 14: 226–34.
61. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol 2003; 14: 281–7.
62. Weinberg JM. Lipotoxicity. Kidney Int 2006; 70 (9): 1560–6.
63. Aitken RJ, Krausz C. Oxidative stress, DNA damage and the Y chromosome. Reproduction 2001; 122: 497–506.
64. Garrido N, Meseguer M, Alvarez J et al. Relationship among standard semen parameters, glutathione peroxidase/glutathione reductase activity, and mRNA expression and reduced glutathione content in ejaculated spermatozoa from fertile and infertile men. Fertil Steril 2004; 82 (Suppl. 3): 1059–66.
65. Sarkar O, Bahrainwala J, Chandrasekaran S et al. Impact of inflammation on male fertility. Front Biosci (Elite Ed) 2011; 3: 89–95.
66. Nguyen RH, Wilcox AJ, Skaerven R et al. Men’s body mass index and infertility. Hum Reprod 2007; 22: 2488–93.
67. Ohwaki K, Endo F, Yano E. Relationship between body mass index and infertility in healthy male Japanese workers: a pilot study. Andrologia 2009; 41: 100–4.
68. Bener A, Al-Ansari AA, Zirie M et al. Is male fertility associated with type 2 diabetes mellitus? Int Urol Nephrol 2009; 41: 777–84.
69. Kort HI, Massey JB, Elsner CW et al. Impact of body mass index values on sperm quantity and quality. J Androl 2006; 27: 450–52.
70. Fejes I, Koloszár S, Szöllosi J et al. Is semen quality affected by male body fat distribution? Andrologia 2005; 37: 155–9.
71. Ali ST, Shaikh RN, Siddiqi AN et al. Semen analysis in insulin-dependent/noninsulin-dependent diabetic men with/without neuropathy. Arch Androl 1993; 30: 47–54.
72. Dohle GR, Diemer T, Giwercman A et al. Male Infertility Guideline. EAU, 2012.
73. Vinik AI, Maser RE, Mitchell BD et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 1553–79.
74. Gilja I, Parazajder J, Radej M et al. Retrograde ejaculation and loss of emission: possibilities of conservative treatment. Eur Urol 1994; 25: 226–8.
75. El-Sakka AI. Premature ejaculation in noninsulin- dependent diabetic patients. Int J Androl 2003; 26: 329–34.
76. Shiraishi K, Takihara H, Matsuyama H. Elevated scrotal temperature, but not varicocele grade, reflects testicular oxidative stress-mediated apoptosis. World J Urol 2010; 28: 359–64.
77. Tsao CW, Hsu CY, Chou YC et al. The relationship between varicoceles and obesity in a young adult population. Int J Androl 2009; 32: 385–90.
78. Handel LN, Shetty R, Sigman M. The relationship between varicoceles and obesity. J Urol 2006; 176: 2138–40.
79. Shafik A, Olfat S. Scrotal lipomatosis. Br J Urol 1981; 53: 50–4.
80. Shafik A, Olfat S. Lipectomy in the treatment of scrotal lipomatosis. Br J Urol 1981; 53: 55–61.
81. Rustenbeck I. Desensitization of insulin secretion. Biochem Pharmacol 2002; 63: 1921–35.
82. Knowler WC, Barrett-Connor E, Fowler SE. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
83. Baron AD. Insulin resistance and vascular function. J Diabetes Complications 2002; 16: 92–102.
84. Palmer NO, Bakos HW, Owens JA et al. Diet and exercise in an obese mouse fed a high-fat diet improve metabolic health and reverse perturbed sperm function. Am J Physiol Endocrinol Metab 2012; 302 (7): 768–80.
85. Tiuzikov I.A., Kalinchenko S.Iu., Vorslov L.O., Tishova Iu.A. Muzhskoe besplodie i insulinorezistentnost': est' li patogeneticheskie sviazi, i kto, kogda i kak dolzhen diagnostirovat' i lechit' ikh? Eksperimental'naia i klinicheskaia urologiia. 2014; 2: 68-75. [in Russian]
86. Blaak E. Gender differences in fat metabolism. Curr Opin Clin Nutr Metab Care 2001; 4: 499–502.
87. Sarkar O, Bahrainwala J, Chandrasekaran S et al. Impact of inflammation on male fertility. Front Biosci (Elite Ed) 2011; 3: 89–95.
88. Tremellen K. Oxidative stress and male infertility – a clinical perspective. Hum Reprod Update 2008; 14 (3): 243–58.
89. McVary KT, Rademaker A, Lloyd GL et al. Autonomic nervous system overactivity in men with lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2005; 174 (4 Pt 1): 1327–33.
90. Sankhla M, Sharma TK, Mathur K et al. Relationship of oxidative stress with obesity and its role in obesity induced metabolic syndrome. Clin Lab 2012; 58 (5–6): 385–92.
91. Tiuzikov I.A. Patologiia muzhskikh polovykh organov kak marker sakharnogo diabeta. Materialy plenuma Rossiiskogo obshchestva urologov. Krasnodar, 2010; s. 292. [in Russian]
92. La Vignera S, Condorelli R, Vicari E et al. Diabetes mellitus and sperm parameters. J Androl 2012; 33 (2): 145–53.
93. Mallidis C, Czerwiec A, Filippi S et al. Spermatogenic and sperm quality differences in an experimental model of metabolic syndrome and hypogonadal hypogonadism. Reproduction 2011; 142 (1): 63–71.
94. Vorslov L.O., Kalinchenko S.Iu., Gadzieva I.V. «Kvartet zdorov'ia» protiv «smertel'nogo kvarteta». Chast' pervaia: metabolicheskaia nevropatiia, legko diagnostirovat', trudno lechit'. Effektivnaia farmakoterapiia. Urologiia. 2013; 1: 32–7. [in Russian]
95. Kalinchenko S.Iu., Vorslov L.O., Kurnikova I.A., Gadzieva I.V. Sovremennyi vzgliad na vozmozhnosti primeneniia al'fa-lipoevoi kisloty. Effektivnaia farmakoterapiia. Urologiia. 2012; 1: 2–8. [in Russian]
96. Vorslov L.O., Tishova Iu.A., Kalinchenko S.Iu. «Kvartet zdorov'ia» protiv «smertel'nogo kvarteta». Chast' vtoraia: defitsit testosterona – strategiia provedeniia zamestitel'noi gormonal'noi terapii. Effektivnaia farmakoterapiia. Urologiia. 2013; 2: 18–22. [in Russian]
97. Ivashkin V.T., Drapkina O.M., Korneeva O.N. Klinicheskie varianty metabolicheskogo sindroma. M.: Meditsinskoe informatsionnoe agentstvo, 2011. [in Russian]
98. Endokrinologiia. Natsional'noe rukovodstvo. Pod. red. I.I.Dedova, G.A.Mel'nichenko. M.: GEOTAR, 2013; s. 473; Demidova T.Iu. Reduksin – novoe sredstvo resheniia starykh problem! Diabet. Obraz zhizni. 2007; 4: 4–7. [in Russian]
99. Romantsova T.I. Osnovnye printsipy reguliatsii energeticheskogo balansa. Consilium Medicum. Endokrinologiia. 2014; 16 (4): 98. [in Russian]
100. Mel'nichenko G.A., Romantsova T.I., Zhuravleva M.V. Vserossiiskaia programma bezopasnogo snizheniia vesa «PrimaVera». Itogi pervogo goda provedeniia. Ozhirenie i metabolizm. 2013; 4, 2013: 82. [in Russian]
101. Бернштейн Л.М. Антидиабетический бугуанид метформин и онкологическая заболеваемость. Сахарный диабет. 2010; 3: 3–6. [in Russian]
102. Knowler WC, Barrett-Connor E, Fowler SE. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 33 (346): 393–403.
103. McNulty SJ et al. A Randomized Trial of Sibutramine in the Management of Obese Type 2 Diabetic Patients Treated With Metformin. Diabets care 2003; 26: 125.
104. Perrielo G, Misericordia P, Volpi E et al. Acute antihyperglycemic mechanism of metformini in NIDDM. Evidence of suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920–8.
105. Bannister CA, Holden SE, Jenkins-Jones S et al. Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab 2014; 16 (11): 1165–73.
106. Tiuzikov I.A., Grekov E.A. Novaia metabolicheskaia kontseptsiia patogeneza idiopaticheskogo muzhskogo besplodiia. Zdravookhranenie Tadzhikistana. 2011; 3: 392–4. [in Russian]
107. Tiuzikov I.A., Kalinchenko S.Iu., Martov A.G. Rol' korrektsii metabolicheskogo statusa pri reproduktivnykh narusheniiakh u muzhchin. Materialy X Vserossiiskogo foruma s mezhdunarodnym uchastiem «Muzhskoe zdorov'e i dolgoletie». M., 2012; s. 95–6. [in Russian]
108. Tiuzikov I.A. Insulinorezistentnost' i muzhskoe besplodie: diagnostika i vozmozhnosti medikamentoznoi korrektsii. Materialy Vserossiickoi nauchno-prakticheskoi konferentsii s mezhdunarodnym uchastiem «Ratsional'naia farmakoterapiia v urologii-2011». M., 2011; s. 148–9. [in Russian]
109. Tiuzikov I.A. Sistemnaia metabolicheskaia terapiia muzhskogo besplodiia, assotsiirovannogo s ozhireniem i insulinorezistentnost'iu. Materialy plenuma Rossiiskogo obshchestva urologov. Kislovodsk, 2011; s. 415–6. [in Russian]
Авторы
С.Ю.Калинченко*1,2, И.А.Тюзиков2, Л.О.Ворслов1,2, Ю.А.Тишова1,2, Е.А.Греков2, А.М.Фомин1,2
1 ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва ул. Миклухо-Маклая, д. 6;
2 ООО «Клиника профессора Калинченко». 123242, Россия, Москва, ул. Зоологическая, д. 2
*info@proandro.ru
1 The Peoples' Friendship University of Russia.117198, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 6;
2 Clinic of Professor Kalinchenko. 123242, Russian Federation, Moscow, ul. Zoologicheskaia, d. 2
*info@proandro.ru
1 ФГАОУ ВО Российский университет дружбы народов. 117198, Россия, Москва ул. Миклухо-Маклая, д. 6;
2 ООО «Клиника профессора Калинченко». 123242, Россия, Москва, ул. Зоологическая, д. 2
*info@proandro.ru
________________________________________________
1 The Peoples' Friendship University of Russia.117198, Russian Federation, Moscow, ul. Miklukho-Maklaia, d. 6;
2 Clinic of Professor Kalinchenko. 123242, Russian Federation, Moscow, ul. Zoologicheskaia, d. 2
*info@proandro.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.